Clinical Trials

HIV drug maker posts loss of $0.36 per share

Published in AIDS Weekly, November 21st, 2005

Incyte Corp. (INCY) announced its third quarter 2005 financial results, revised its 2005 financial guidance and updated shareholders on recent developments, including a net loss for the quarter ended September 30, 2005 of $30.2 million, or $0.36 per share, as compared to $26.0 million, or $0.35 per share, for the same period in 2004..

As of September 30, 2005, cash and short-term investments totaled $364.0 million, compared to $469.8 million as of December 31, 2004. The decrease is a result of the company's use of cash of approximately $75.7 million to support operations and an additional $35.8 million to repurchase and retire its 5.5% convertible subordinated...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2005-11-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry